Dyne Therapeutics, Inc (DYN)

$41.54

-0.42

(-1%)

Market is closed - opens 7 PM, 15 Jul 2024

Insights on Dyne Therapeutics, Inc

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 222.8% return, outperforming this stock by 122.0%

Performance

  • $40.97
    $42.21
    $41.54
    downward going graph

    1.37%

    Downside

    Day's Volatility :2.94%

    Upside

    1.59%

    downward going graph
  • $6.40
    $42.31
    $41.54
    downward going graph

    84.59%

    Downside

    52 Weeks Volatility :84.87%

    Upside

    1.82%

    downward going graph

Returns

PeriodDyne Therapeutics, IncSector (Health Care)Index (Russel 2000)
3 Months
62.32%
6.1%
0.0%
6 Months
151.41%
4.9%
0.0%
1 Year
260.79%
13.6%
0.0%
3 Years
100.77%
14.3%
-22.5%

Highlights

Market Capitalization
4.2B
Book Value
$5.49
Earnings Per Share (EPS)
-3.98
PEG Ratio
0.19
Wall Street Target Price
46.67
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-40.98%
Return On Equity TTM
-71.5%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-264.2M
Diluted Eps TTM
-3.98
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.01
EPS Estimate Next Year
-3.07
EPS Estimate Current Quarter
-0.8
EPS Estimate Next Quarter
-0.81

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Dyne Therapeutics, Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
11
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 12.35%

Current $41.54
Target $46.67

Technicals Summary

Sell

Neutral

Buy

Dyne Therapeutics, Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Dyne Therapeutics, Inc
Dyne Therapeutics, Inc
27.11%
151.41%
260.79%
100.77%
75.56%
Moderna, Inc.
Moderna, Inc.
-16.86%
15.92%
-2.46%
-48.68%
764.93%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.12%
15.76%
50.37%
88.19%
269.25%
Novo Nordisk A/s
Novo Nordisk A/s
-2.42%
30.45%
80.67%
222.84%
488.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.43%
13.55%
42.21%
148.12%
179.95%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Dyne Therapeutics, Inc
Dyne Therapeutics, Inc
NA
NA
0.19
-3.01
-0.71
-0.41
NA
5.49
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.64
31.64
1.46
44.29
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.22
49.22
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.94
31.94
0.53
17.02
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Dyne Therapeutics, Inc
Dyne Therapeutics, Inc
Buy
$4.2B
75.56%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$47.1B
764.93%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$118.0B
269.25%
31.64
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$635.7B
488.09%
49.22
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.9B
179.95%
31.94
39.46%

Institutional Holdings

  • FCPM III SERVICES BV

    7.89%
  • BlackRock Inc

    5.42%
  • RA Capital Management, LLC

    4.98%
  • Deep Track Capital, LP

    4.58%
  • State Street Corporation

    4.22%
  • Mpm Asset Management, LLC

    3.47%

Corporate Announcements

  • Dyne Therapeutics, Inc Earnings

    Dyne Therapeutics, Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

dyne therapeutics, inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the united states. it develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its force platform that delivers disease-modifying therapies. the company was founded in 2017 and is based in waltham, massachusetts.

Organization
Dyne Therapeutics, Inc
Employees
143
CEO
Ms. Susanna Gatti High M.B.A.
Industry
Commercial Services

FAQs